Beam Therapeutics (BEAM) announced the company will encore data from the BEACON Phase 1/2 clinical trial of BEAM-101 in sickle cell disease in an oral presentation at the 2025 Tandem Meetings Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy, ASTCT, and Center for International Blood and Marrow Transplant Research, CIBMTR, taking place February 12 – 15, 2025, in Honolulu, Hawaii. The safety profile of BEAM-101 was consistent with busulfan conditioning and autologous hematopoietic stem cell transplantation. Beam expects to present updated data from the BEACON trial in mid-2025.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM: